RealWorld Dynamix™: Biologic and Otezla Switching in PsA 2017

Spherix Global Insights has released the 2017 update of RealWorld Dynamix: PsA based on analysis of 1,008 PsA patient charts. The large scale chart audit was completed by about 200 rheumatologists and focuses on patients that have been switched between biologic brands and/or Otezla during the past three months. In addition to comparisons from the previous study, published in Q1 2016, the audit is a critical supplement to claims data in that it provides a full complement of patient social and clinical demographics, the physician rationale and intent with regard to treatment choices, lab values and assessments and guidance on the next likely switch.

Click the button below to download highlights from this report.

RWD: Biologic and Otezla Switching in PsA

2017-06-18T12:58:38+00:00